Search results
Results from the WOW.Com Content Network
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, ... Assuming they can treat 20,000 patients at an average price of $1.5 million, it could be a $30 ...
When the company reported VK2735's phase 2 results last year, the stock jumped 121% in one trading session. Viking gave back some of those gains, but still finished the year, as mentioned above ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Viking Therapeutics wasn’t one of them. The 10 stocks that ...
In the third quarter, the company's revenue of $2.77 billion increased by 12% year over year, a strong performance for a biotech giant. The company's best CF treatment yet, Trikafta, accounted for ...
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an impressive resume already, but it's just getting started. It's currently in the ...
See the 10 stocks » *Stock Advisor returns as of September 3, 2024. Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Goldman Sachs ...
Its share price has plunged over 30% this year. Moderna is roughly 86% below its peak set in 2021. However, I think this beaten-down biotech stock could realistically be one of the biggest winners ...
In the second quarter, the company's top line soared by 39% year over year to $362.9 million. The biotech turned an adjusted net loss of $1.01 in the second quarter of 2023 into an adjusted net ...